Dialysis drug showdown: which vitamin d works best?
NCT ID NCT07640347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two vitamin D medications—doxercalciferol (given through a vein) and calcitriol (taken by mouth)—to see which is better at lowering parathyroid hormone levels in kidney dialysis patients. About 98 adults on dialysis with high parathyroid hormone will take part. The goal is to find a more effective way to manage this common complication and reduce bone and heart risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWERING PARATHYROID HORMONE LEVEL IN PATIENTS ON HEMODIOALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood test could end painful bone biopsies for kidney disease patients
- New blood test may reveal bone health in kids on dialysis
- Tiny study tracks kidney Drug's exit route in dialysis patients
- New hope for kids with kidney disease: experimental vitamin d pill enters trial
- New drug SHR6508 aims to tame hormone imbalance in dialysis patients
- New drug aims to tame parathyroid glands in dialysis patients